Collegium Pharmaceutical (COLL) said Monday that it signed an accelerated share repurchase deal with Jefferies to repurchase $25 million of its common shares.
The deal is part of the company's $150 million share repurchase program that was approved by its board in January 2024, according to the statement.
Collegium Pharmaceutical said it will pay $25 million to Jefferies in exchange for an initial delivery of 692,281 common shares, which is about 80% of the shares that it expects to buy back under the accelerated share repurchase deal.
The company said the final amount of shares will be based on the volume-weighted average prices of its shares over the term of the accelerated share repurchase agreement, subject to certain adjustments.
Price: 29.86, Change: +0.97, Percent Change: +3.34
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。